Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Credit Suisse 31st Annual Healthcare Conference
A virtual presentation will be made live starting on Tuesday, November 8, 2022
Stifel 2022 Healthcare Conference
Fireside chat: Wednesday, November 16, 2022 at 10:20 am EST
Location: Lotte New York Palace Hotel, New York, NY
Jefferies London Healthcare Conference
Fireside chat: Thursday, November 17, 2022 at 3:15 pm GMT (10:15 am EST)
Location: The Waldorf Hilton, London, UK
A live webcast and archived replay of the fireside chats along with a replay of the pre-recorded presentation will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.82 |
| Daily Change: | 0.02 2.98 |
| Daily Volume: | 210,381 |
| Market Cap: | US$55.750M |
November 07, 2024 September 05, 2024 March 20, 2024 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE
